DEXCOM INC — Director's Dealing 2023

Mar 10, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2023-03-08

Reporting Person: SAYER KEVIN R (Director, President CEO and Chairman of)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-03-08	Common Stock	A	54422	$0.001	Acquired	385759	Direct

Footnotes

F1: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

F2: Included in this number are 115,682 unvested restricted stock units, 54,422 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 43,336 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 17,924 of which were granted on March 8, 2021 and shall vest through March 8, 2024.